Jason McCarthy

Mind Medicine (MindMed) Inc (NASDAQ: MNMD) shares traded higher by 3.3% on Monday after one analyst initiated bullish coverage of the psychedelics stock. The Analyst: Maxim analyst Jason McCarthy initiated coverage of MindMed with a Buy rating and $6 price target. The Thesis: McCarthy...

At the Benzinga Global Small Cap Conference Thursday, Jason McCarthy, senior managing director at Maxim Group, hosted a panel discussion on how biotech companies are getting back to fundamentals following an extremely disruptive period during the COVID-19 pandemic. The panel discussion included...

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is set to begin a new phase, according to Maxim Group, after undergoing several changes in strategy, management, capital structure and financing through 2020 and into 2021. The Titan Pharmaceuticals Analyst: Jason McCarthy upgraded the...

Viking Therapeutics Inc (NASDAQ: VKTX) shares more than doubled Thursday after a 145-percent jump in shares of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), which announced data from a Phase 2 study of its non-alcoholic steatohepatitis pipeline candidate. NASH is a form of non-alcoholic...

Extended Medicare reimbursement for Omeros Corporation (NASDAQ: OMER)’s OMIDRIA, along with the company’s increased focus on OMS721 trials, will act as solid short- and long-term drivers, according to Maxim Group. The Analyst Jason McCarthy of Maxim Group maintained a Buy rating...

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) lost a bull in February on Aramchol’s failed ARRIVE study for HIV-related fatty liver disease. However, the drug is now generating optimism for distinct indications. The Analyst Maxim Group analyst Jason McCarthy upgraded Galmed to Buy and...

Bluebird bio Inc (NASDAQ: BLUE)'s stock has soared more than 200 percent since the start of 2017, with notable strength coming after the company released impressive data results at the American Society of Hematology conference. The Analyst Maxim Group's Jason McCarthy downgraded bluebird...

Gilead Sciences, Inc. (NASDAQ: GILD) stands to benefit on multiple fronts, which prompted an analyst to upgrade the shares of the company Thursday. The Analyst Maxim Group analyst Jason McCarthy upgraded his rating on the shares of Gilead Sciences from Hold to Buy and  set a $94 price...

OncoSec Medical Inc (NASDAQ: ONCS) shares spiked about 20 percent intraday Thursday amid the release of positive mid-stage trial data for its investigational therapy ImmuoPulse IL-12 as a monotherapy and in combination with Pembrolizumab (Keytruda) for treating predicted anti-PD-1 non-responder...

Shares of Agenus Inc (NASDAQ: AGEN) were trading up more than 9 percent on Friday afternoon, after Maxim Group upgraded its rating on the stock from Hold to Buy, while establishing a price target of $7.00. Analysts Jason McCarthy and Jason Kolbert highlighted a few elements behind their...